<DOC>
	<DOCNO>NCT00701272</DOCNO>
	<brief_summary>The main objective study ass whether recently-developed bioassay molecule `` secrete fibrinogen-like protein 2 '' ( sFGL2 ) use predict recurrence and/or progression Hepatitis C Virus disease post liver transplant patient . The hypothesis patient chronic HCV high normal level sFGL2 blood pre- post-transplantation inhibit ability clear HCV , influence progression HCV disease recurs .</brief_summary>
	<brief_title>FGL2/Fibroleukin Hepatitis C Virus Recurrence Post Liver Transplantation</brief_title>
	<detailed_description>Hepatitis C Virus infection ( HCV ) serious health problem worldwide , account significant morbidity mortality . The current treatment , combination therapy pegylated IFNa/ribavirin result 50 % sustained viral response HCV lead indication liver transplantation . Unfortunately , HCV recurrence post-transplantation universal often difficult distinguish recurrent HCV process rejection , lead inappropriate delay treatment ( ) compound graft damage . It would beneficial access circulate biomarker distinguish HCV disease recurrence process predict severity HCV disease progression post-transplantation . The molecule FGL2 secrete cell immune system may key immunomodulator affect graft survival HCV recurrence . The aim study ass whether bioassay FGL2 predict HCV disease recurrence progression liver transplantation and/or differentiate HCV disease recurrence acute cellular rejection . This study also examine form Fc Receptor express patient . The Fc receptor hypothesize binding partner FGL2 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>For HCV positive subject : 1 . Able willing give write informed consent 2 . Willing follow study protocol 3 . Diagnosis chronic HCV infection base two positive serology test 4 . No history active alcohol drug abuse 5 . All six viral genotype consider 6 . Pre post transplant viral load data must available 1 . Pregnancy 2 . HBV , HDV HIV coinfection For NonHCV subject : 1 . Able willing give write informed consent 2 . Willing follow study protocol 1 . Free infection follow : HCV , HBV , HDV HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>